The present disclosure provides compositions and methods related to the detection of an analyte-of-interest. In particular, the present disclosure provides compositions and methods related to the detection and/or quantification of an analyte-of-interest using a signal detection component in combination with a signal amplification component. By combining these components in a modular format, cell-free synthetic gene circuits can be generated or improved to address a specific biological or biomedical diagnostic need.

The present disclosure provides compositions and methods related to the detection of an analyte-of-interest. In particular, the present disclosure provides compositions and methods related to the detection and/or quantification of an analyte-of-interest using a signal detection component in combination with a signal amplification component. By combining these components in a modular format, cell-free synthetic gene circuits can be generated or improved to address a specific biological or biomedical diagnostic need.

Provided herein are methods of normalizing a population of nucleic acid samples. Methods herein can comprise: contacting a plurality of nucleic acid samples to a normalizing agent, wherein each nucleic acid of the plurality comprises a sample-specific barcode, and wherein the normalizing agent comprises a plurality of labeled enzymes capable of binding to each sample specific barcode; contacting the product to a capture agent to capture the nucleic acids that are bound to the normalizing agent; and treating the product with a protease to release the bound nucleic acids, thereby creating a normalized library having more even representation of each nucleic acid sample than the plurality of nucleic acid samples before normalization.

Provided herein are methods of normalizing a population of nucleic acid samples. Methods herein can comprise: contacting a plurality of nucleic acid samples to a normalizing agent, wherein each nucleic acid of the plurality comprises a sample-specific barcode, and wherein the normalizing agent comprises a plurality of labeled enzymes capable of binding to each sample specific barcode; contacting the product to a capture agent to capture the nucleic acids that are bound to the normalizing agent; and treating the product with a protease to release the bound nucleic acids, thereby creating a normalized library having more even representation of each nucleic acid sample than the plurality of nucleic acid samples before normalization.

Under one aspect, a composition includes a substrate; a first polynucleotide coupled to the substrate; a second polynucleotide hybridized to the first polynucleotide; and a catalyst coupled to a first nucleotide of the second polynucleotide, the catalyst being operable to cause a chemiluminogenic molecule to emit a photon. Under another aspect, a method includes providing a catalyst operable to cause a first chemiluminogenic molecule to emit a photon; providing a substrate; providing a first polynucleotide coupled to the substrate; hybridizing a second polynucleotide to the first polynucleotide; coupling a first quencher to a first nucleotide of the second polynucleotide; and inhibiting, by the first quencher, photon emission by the first chemiluminogenic molecule.

Methods and compositions for attaching cell-specific barcodes without formation of partitions is provided.

Methods and compositions for attaching cell-specific barcodes without formation of partitions is provided.

Embodiments herein describe systems and methods to identify genetic silencers. Many embodiments screen one or more DNA fragments to identify sequences that are capable of silencing gene expression. Once identified, silencer elements can be utilized for many applications, including precision medicine.

Embodiments herein describe systems and methods to identify genetic silencers. Many embodiments screen one or more DNA fragments to identify sequences that are capable of silencing gene expression. Once identified, silencer elements can be utilized for many applications, including precision medicine.

Disclosed herein are in vitro methods of multiple staining and slide preparation for a cytopathological sample, such as a urine sample. These methods enable simultaneous staining of biomarkers and cytopathological stains to greatly enhance confidence in identifying atypical cells such as cancer cells. Also disclosed herein are methods of using said staining and preparation methods for the detection of bladder cancer using urine samples from a patient. These methods offer increased sensitivity and specificity over conventional bladder cancer detection methods. Also disclosed herein are the urinary exfoliated cells stained according to the methods provided herein.